Higher Lenalidomide Dosing Safe in Renal Impairment

Data from the REMNANT study shows that higher-than-recommended lenalidomide dosing is safe and effective in transplant-eligible patients with newly diagnosed multiple myeloma and renal impairment. Presenting the findings, Frida Bugge Askeland, MD, PhD student, Consultant Physician at Oslo Myeloma Center, Oslo University Hospital, Norway, highlights that most patients achieve renal responses, including several dialysis-dependent patients who become dialysis-independent.